Literature DB >> 9733786

Fidelity and mutational specificity of uracil-initiated base excision DNA repair synthesis in human glioblastoma cell extracts.

R J Sanderson1, D W Mosbaugh.   

Abstract

The fidelity of DNA synthesis associated with uracil-initiated base excision repair was measured in human whole cell extracts. An M13mp2 lacZalpha DNA-based reversion assay was developed to assess the error frequency of DNA repair synthesis at a site-specific uracil residue. All three possible base substitution errors were detected at the uracil target causing reversion of opal codon 14 in the Escherichia coli lacZalpha gene. Using human glioblastoma U251 whole cell extracts, approximately 50% of the heteroduplex uracil-containing DNA substrate was completely repaired, as determined by the insensitivity of form I DNA reaction products to cleavage by a combined treatment of E. coli uracil-DNA glycosylase and endonuclease IV. The majority of repair occurred by the uracil-initiated base excision repair pathway, since the addition of the bacteriophage PBS2 uracil-DNA glycosylase inhibitor protein to extracts significantly blocked this process. In addition, the formation of repaired form I DNA molecules occurred concurrently with limited DNA synthesis, which was largely restricted to the HinfI DNA fragment initially containing the uracil residue and specific to the uracil-containing DNA strand. Based on the reversion frequency of repaired M13mp2 DNA, the fidelity of DNA repair synthesis at the target was determined to be about one misincorporated nucleotide per 1900 repaired uracil residues. The major class of base substitutions propagated transversion mutations, which were distributed almost equally between T to G and T to A changes in the template. A similar mutation frequency was also observed using whole cell extracts from human colon adenocarcinoma LoVo cells, suggesting that mismatch repair did not interfere with the fidelity measurements.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9733786     DOI: 10.1074/jbc.273.38.24822

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  7 in total

1.  Physical and functional interaction of human nuclear uracil-DNA glycosylase with proliferating cell nuclear antigen.

Authors:  Rinkei Ko; Samuel E Bennett
Journal:  DNA Repair (Amst)       Date:  2005-10-07

2.  Direct interaction between XRCC1 and UNG2 facilitates rapid repair of uracil in DNA by XRCC1 complexes.

Authors:  Mansour Akbari; Karin Solvang-Garten; Audun Hanssen-Bauer; Nora Valeska Lieske; Henrik Sahlin Pettersen; Grete Klippenvåg Pettersen; David M Wilson; Hans E Krokan; Marit Otterlei
Journal:  DNA Repair (Amst)       Date:  2010-05-13

3.  Escherichia coli nucleoside diphosphate kinase does not act as a uracil-processing DNA repair nuclease.

Authors:  Samuel E Bennett; Cheng-Yao Chen; Dale W Mosbaugh
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-19       Impact factor: 11.205

4.  Age, sex, and race influence single-strand break repair capacity in a human population.

Authors:  Andrzej R Trzeciak; Janice Barnes; Ngozi Ejiogu; Kamala Foster; Larry J Brant; Alan B Zonderman; Michele K Evans
Journal:  Free Radic Biol Med       Date:  2008-09-17       Impact factor: 7.376

5.  A meta-analysis on XRCC1 and XRCC3 polymorphisms and colorectal cancer risk.

Authors:  Zheng Jiang; Chunxiang Li; Ye Xu; Sanjun Cai
Journal:  Int J Colorectal Dis       Date:  2009-11-14       Impact factor: 2.571

Review 6.  Biological and therapeutic relevance of nonreplicative DNA polymerases to cancer.

Authors:  Jason L Parsons; Nils H Nicolay; Ricky A Sharma
Journal:  Antioxid Redox Signal       Date:  2012-09-05       Impact factor: 8.401

7.  Transcriptional network analysis reveals that AT1 and AT2 angiotensin II receptors are both involved in the regulation of genes essential for glioma progression.

Authors:  Hátylas Azevedo; André Fujita; Silvia Yumi Bando; Priscila Iamashita; Carlos Alberto Moreira-Filho
Journal:  PLoS One       Date:  2014-11-03       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.